Literature DB >> 16377688

Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Keith M Olsen1, Martha Gentry-Nielsen, Mei Yue, Mary U Snitily, Laurel C Preheim.   

Abstract

This investigation compared the effect of ethanol on fluoroquinolone antibiotic efficacy and pharmacodynamics in an ethanol-fed rat model of pneumococcal pneumonia. Male Sprague-Dawley rats received a liquid diet containing 36% of total calories as ethanol. Paired controls (pair-fed controls) were fed a liquid diet without ethanol or received rat chow. Diets began 7 days before and continued for 10 days after transtracheal infections with 10 times the 50% lethal dose of type 3 Streptococcus pneumoniae. Beginning 18 h after infection, the rats received once daily subcutaneous phosphate-buffered saline, levofloxacin, moxifloxacin, or trovafloxacin at 50 or 100 mg/kg of body weight. White blood cell counts were determined, blood samples were collected for culture, and mortality was recorded. Additional rats were killed on day 5 for pharmacodynamic studies and quantitative cultures of bronchoalveolar lavage fluid. Bacteremia occurred by day 3 in 20 of 22 untreated rats. All 22 untreated rats died by day 9. Moxifloxacin treatment was effective in all diet groups at both the 50- and 100-mg/kg doses. In contrast, 50-mg/kg doses of levofloxacin and trovafloxacin improved survival in ethanol-fed rats but were ineffective in chow-fed rats. High-dose trovafloxacin at 100 mg/kg was associated with increased mortality in pair-fed rats. The free-fraction area under the concentration-time curve/MIC ratio exceeded 50 with all antibiotics in the ethanol group but dropped below 30 with levofloxacin and trovafloxacin in the pair- and chow-fed rats, with higher mortality. Achievement of adequate antibiotic-free fraction area under the concentration-time curve/MIC ratios helps overcome ethanol-induced immune defects induced in experimental pneumococcal pneumonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377688      PMCID: PMC1346821          DOI: 10.1128/AAC.50.1.210-219.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

Authors:  J M Blondeau
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

3.  Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.

Authors:  David P Nicolau; Holly M Mattoes; Maryanne Banevicius; Dawei Xuan; Charles H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.

Authors:  Victor L Yu; Christine C C Chiou; Charles Feldman; Ake Ortqvist; Jordi Rello; Arthur J Morris; Larry M Baddour; Carlos M Luna; David R Snydman; Margaret Ip; Wen Chien Ko; M Bernadete F Chedid; Antoine Andremont; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2003-07-07       Impact factor: 9.079

6.  Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.

Authors:  Archie C Perry; Branko Prpa; Mark S Rouse; Kerryl E Piper; Arlen D Hanssen; James M Steckelberg; Robin Patel
Journal:  Clin Orthop Relat Res       Date:  2003-09       Impact factor: 4.176

7.  Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.

Authors:  Martin H Ellbogen; Keith M Olsen; Martha J Gentry-Nielsen; Laurel C Preheim
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

8.  Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography.

Authors:  F C Cheng; T R Tsai; Y F Chen; L C Hung; T H Tsai
Journal:  J Chromatogr A       Date:  2002-06-28       Impact factor: 4.759

9.  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

Authors:  Lala M Dunbar; Richard G Wunderink; Michael P Habib; Leon G Smith; Alan M Tennenberg; Mohammed M Khashab; Barbara A Wiesinger; Jim X Xiang; Neringa Zadeikis; James B Kahn
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more
  6 in total

Review 1.  Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.

Authors:  Kari A Mergenhagen; Bethany A Wattengel; Megan K Skelly; Collin M Clark; Thomas A Russo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.

Authors:  Liqin Zhu; Yuan Zhang; Jianwei Yang; Yongming Wang; Jianlei Zhang; Yuanyuan Zhao; Weilin Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-10       Impact factor: 2.441

Review 3.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

Review 4.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

5.  Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats.

Authors:  Hussam M Gharib; Mohammad Y Abajy; Abdulnaser Omaren
Journal:  Heliyon       Date:  2020-04-24

6.  Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Authors:  Myriam V Valenzuela; Mirian Domenech; Patricia Mateos-Martínez; Fernando González-Camacho; Adela G de la Campa; Maria Teresa García
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.